[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock rises Monday, still underperforms market",
    "summary": "Gilead Sciences Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=8384bcb8edc6f53580145c39d16563fd70c57f654701f5d1edcaab9424a45238",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731948120,
      "headline": "Gilead Sciences Inc. stock rises Monday, still underperforms market",
      "id": 131476045,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=8384bcb8edc6f53580145c39d16563fd70c57f654701f5d1edcaab9424a45238"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Livdelzi shows promise in PBC clinical trial",
    "summary": "The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.",
    "url": "https://finnhub.io/api/news?id=66f012565c751fa443aaab5195f0c1c198e9c75244fd95c4c80a9bc891eade9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731941279,
      "headline": "Gilead’s Livdelzi shows promise in PBC clinical trial",
      "id": 131452009,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/CTA-3-Gileadd-Shutterstock_2061393599.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.",
      "url": "https://finnhub.io/api/news?id=66f012565c751fa443aaab5195f0c1c198e9c75244fd95c4c80a9bc891eade9f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis",
    "summary": "FOSTER CITY, Calif. - Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with primary...",
    "url": "https://finnhub.io/api/news?id=57f580e0d7c3fad8920731252632ddc364dbcfb9fe8075663e0873b6ed584bef",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913531,
      "headline": "Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis",
      "id": 131439981,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY, Calif. - Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with primary...",
      "url": "https://finnhub.io/api/news?id=57f580e0d7c3fad8920731252632ddc364dbcfb9fe8075663e0873b6ed584bef"
    }
  }
]